Critical reappraisal of remdesivir investigational trials in COVID-19

During disease outbreaks, the pharmaceutical industry generally puts a lot of effort into promoting clinical trials studying their new drugs. We review evidence of the ten most recent reports on remdesivir. We conclude that it is far too premature to identify remdesivir as a curative or life-saving...

Descripción completa

Detalles Bibliográficos
Autores principales: Brouqui, P., Giraud-Gatineau, A., Raoult, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Mini-Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567956/
https://www.ncbi.nlm.nih.gov/pubmed/33088576
http://dx.doi.org/10.1016/j.nmni.2020.100745
_version_ 1783596432620519424
author Brouqui, P.
Giraud-Gatineau, A.
Raoult, D.
author_facet Brouqui, P.
Giraud-Gatineau, A.
Raoult, D.
author_sort Brouqui, P.
collection PubMed
description During disease outbreaks, the pharmaceutical industry generally puts a lot of effort into promoting clinical trials studying their new drugs. We review evidence of the ten most recent reports on remdesivir. We conclude that it is far too premature to identify remdesivir as a curative or life-saving intervention during the COVID-19 pandemic.
format Online
Article
Text
id pubmed-7567956
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75679562020-10-20 Critical reappraisal of remdesivir investigational trials in COVID-19 Brouqui, P. Giraud-Gatineau, A. Raoult, D. New Microbes New Infect Mini-Review During disease outbreaks, the pharmaceutical industry generally puts a lot of effort into promoting clinical trials studying their new drugs. We review evidence of the ten most recent reports on remdesivir. We conclude that it is far too premature to identify remdesivir as a curative or life-saving intervention during the COVID-19 pandemic. Elsevier 2020-09-28 /pmc/articles/PMC7567956/ /pubmed/33088576 http://dx.doi.org/10.1016/j.nmni.2020.100745 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Mini-Review
Brouqui, P.
Giraud-Gatineau, A.
Raoult, D.
Critical reappraisal of remdesivir investigational trials in COVID-19
title Critical reappraisal of remdesivir investigational trials in COVID-19
title_full Critical reappraisal of remdesivir investigational trials in COVID-19
title_fullStr Critical reappraisal of remdesivir investigational trials in COVID-19
title_full_unstemmed Critical reappraisal of remdesivir investigational trials in COVID-19
title_short Critical reappraisal of remdesivir investigational trials in COVID-19
title_sort critical reappraisal of remdesivir investigational trials in covid-19
topic Mini-Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567956/
https://www.ncbi.nlm.nih.gov/pubmed/33088576
http://dx.doi.org/10.1016/j.nmni.2020.100745
work_keys_str_mv AT brouquip criticalreappraisalofremdesivirinvestigationaltrialsincovid19
AT giraudgatineaua criticalreappraisalofremdesivirinvestigationaltrialsincovid19
AT raoultd criticalreappraisalofremdesivirinvestigationaltrialsincovid19

Ejemplares similares